Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.
Secretin, a gastrointestinal (GI) peptide, may offer therapeutic benefit in autism. Autistic features can also be present in schizophrenia and a recent study suggested a role for adjunctive secretin in treatment-resistant schizophrenia. The current report describes one patient with undifferentiated schizophrenia and prominent autistic features who received a single dose of secretin and demonstrated substantial yet transient improvement. The case illustrates the potential role of secretin as a novel adjunctive treatment strategy in schizophrenic patients with autistic features.
Alamy
Sayed S
SS
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7160, USA.
Jarskog
L Fredrik
LF
Sheitman
Brian B
BB
Lieberman
Jeffrey A
JA
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001321:Autistic Disorder / Q000150:complications*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012633:Secretin / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D012633:Secretin